Chronic treatment with anesthetic propofol improves cognitive function and attenuates caspase activation in both aged and Alzheimer's disease transgenic mice

Journal of Alzheimer's Disease

Volumn 41, Issue 2, 2014, Pages 499-513

  Shao, Haijun ^a,b   Zhang, Yiying ^a   Dong, Yuanlin ^a   Yu, Buwei ^b   Xia, Weiming ^c   Xie, Zhongcong ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Aging; Alzheimer's disease; Amyloid ? protein; Anesthesia; Apoptosis; Mitochondria; Neurodegeneration; Propofol

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CASPASE; CASPASE 3; CASPASE 8; CASPASE 9; FLUMAZENIL; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PROPOFOL;

AGED; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APP GENE; ARTICLE; COGNITION; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVATION; FLOW CYTOMETRY; GENE; HUMAN; HUMAN CELL; LONG TERM CARE; MORRIS WATER MAZE TEST; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PSEN1 GENE; SEDATION; SENILE PLAQUE; TRANSGENIC MOUSE; WESTERN BLOTTING; WILD TYPE MOUSE;

EID: 84927565650     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-132792     Document Type: Article

References (61)

1. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010; 362:329-344. [PubMed: 20107219]
2. Aisen PS, Cummings J, Schneider LS. Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. Cold Spring Harb Perspect Med. 2012; 2:a006395. [PubMed: 22393531]
3. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014; 370:322-333. [PubMed: 24450891]
4. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014; 370:311-321. [PubMed: 24450890]
5. Holtzman DM, Deshmukh M. Caspases: A treatment target for neurodegenerative disease? Nat Med. 1997; 3:954-955. [PubMed: 9288715]
6. Lunkes A, Trottier Y, Mandel JL. Pathological mechanisms in Huntington's disease and other polyglutamine expansion diseases. Essays Biochem. 1998; 33:149-163. [PubMed: 10488448]
7. Namura S, Zhu J, Fink K, Endres M, Srinivasan A, Tomaselli KJ, Yuan J, Moskowitz MA. Activation and cleavage of caspase-3 in apoptosis induced by experimental cerebral ischemia. J Neurosci. 1998; 18:3659-3668. [PubMed: 9570797]
8. Kim TW, Pettingell WH, Jung YK, Kovacs DM, Tanzi RE. Alternative cleavage of Alzheimerassociated presenilins during apoptosis by a caspase-3 family protease. Science. 1997; 277:373-376. [PubMed: 9219695]
9. Loetscher H, Deuschle U, Brockhaus M, Reinhardt D, Nelboeck P, Mous J, Grunberg J, Haass C, Jacobsen H. Presenilins are processed by caspase-type proteases. J Biol Chem. 1997; 272:20655-20659. [PubMed: 9252383]
10. Barnes NY, Li L, Yoshikawa K, Schwartz LM, Oppenheim RW, Milligan CE. Increased production of amyloid precursor protein provides a substrate for caspase-3 in dying motoneurons. J Neurosci. 1998; 18:5869-5880. [PubMed: 9671674]
11. Kovacs DM, Mancini R, Henderson J, Na SJ, Schmidt SD, Kim TW, Tanzi RE. Staurosporineinduced activation of caspase-3 is potentiated by presenilin 1 familial Alzheimer's disease mutations in human neuroglioma cells. J Neurochem. 1999; 73:2278-2285. [PubMed: 10582585]
12. Su JH, Anderson AJ, Cummings BJ, Cotman CW. Immunohistochemical evidence for apoptosis in Alzheimer's disease. Neuroreport. 1994; 5:2529-2533. [PubMed: 7696596]
13. Su JH, Deng G, Cotman CW. Bax protein expression is increased in Alzheimer's brain: Correlations with DNA damage, Bcl-2 expression, and brain pathology. J Neuropathol Exp Neurol. 1997; 56:86-93. [PubMed: 8990132]
14. Tesco G, Koh YH, Kang EL, Cameron AN, Das S, Sena-Esteves M, Hiltunen M, Yang SH, Zhong Z, Shen Y, Simpkins JW, Tanzi RE. Depletion of GGA3 stabilizes BACE and enhances betasecretase activity. Neuron. 2007; 54:721-737. [PubMed: 17553422]
15. Mattson MP. Contributions of mitochondrial alterations, resulting from bad genes and a hostile environment, to the pathogenesis of Alzheimer's disease. Int Rev Neurobiol. 2002; 53:387-409. [PubMed: 12512347]
16. Raina AK, Hochman A, Ickes H, Zhu X, Ogawa O, Cash AD, Shimohama S, Perry G, Smith MA. Apoptotic promoters and inhibitors in Alzheimer's disease: Who wins out? Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27:251-254. [PubMed: 12657364]
17. LeBlanc AC. The role of apoptotic pathways in Alzheimer's disease neurodegeneration and cell death. Curr Alzheimer Res. 2005; 2:389-402. [PubMed: 16248844]
18. Cribbs DH, Poon WW, Rissman RA, Blurton-Jones M. Caspase-mediated degeneration in Alzheimer's disease. Am J Pathol. 2004; 165:353-355. [PubMed: 15277211]
19. Burguillos MA, Deierborg T, Kavanagh E, Persson A, Hajji N, Garcia-Quintanilla A, Cano J, Brundin P, Englund E, Venero JL, Joseph B. Caspase signalling controls microglia activation and neurotoxicity. Nature. 2011; 472:319-324. [PubMed: 21389984]
20. Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2009; 106:14670-14675. [PubMed: 19667196]
21. Zhu X, Perry G, Smith MA, Wang X. Abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease. J Alzheimers Dis. 2013; 33(Suppl 1):S253-S262. [PubMed: 22531428]
22. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov. 2010; 9:447-464. [PubMed: 20467424]
23. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev. 2007; 87:99-163. [PubMed: 17237344]
24. Sullivan PG, Rabchevsky AG, Waldmeier PC, Springer JE. Mitochondrial permeability transition in CNS trauma: Cause or effect of neuronal cell death? J Neurosci Res. 2005; 79:231-239. [PubMed: 15573402]
25. Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, LeBlanc A, Smith D, Rigby M, Shearman MS, Clarke EE, Zheng H, Van Der Ploeg LH, Ruffolo SC, Thornberry NA, Xanthoudakis S, Zamboni RJ, Roy S, Nicholson DW. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell. 1999; 97:395-406. [PubMed: 10319819]
26. Stadelmann C, Deckwerth TL, Srinivasan A, Bancher C, Bruck W, Jellinger K, Lassmann H. Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death. Am J Pathol. 1999; 155:1459-1466. [PubMed: 10550301]
27. Louneva N, Cohen JW, Han LY, Talbot K, Wilson RS, Bennett DA, Trojanowski JQ, Arnold SE. Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer's disease. Am J Pathol. 2008; 173:1488-1495. [PubMed: 18818379]
28. Limon A, Reyes-Ruiz JM, Miledi R. Loss of functional GABA(A) receptors in the Alzheimer diseased brain. Proc Natl Acad Sci U S A. 2012; 109:10071-10076. [PubMed: 22691495]
29. Hales TG, Lambert JJ. The actions of propofol on inhibitory amino acid receptors of bovine adrenomedullary chromaffin cells and rodent central neurones. Br J Pharmacol. 1991; 104:619-628. [PubMed: 1665745]
30. Zhang Y, Zhen Y, Dong Y, Xu Z, Yue Y, Golde TE, Tanzi RE, Moir RD, Xie Z. Anesthetic propofol attenuates the isoflurane-induced caspase-3 activation and abeta oligomerization. PLoS One. 2011; 6:e27019. [PubMed: 22069482]
31. Pryor K, Blackstock-Bernstein AS, Feiler D, Vortsman E, Root JC. Administration of propofol after learning improves memory performance in human subjects via loss of competitive consolidation: Evidence that propofol amnesia occurs at the induction of consolidation. American Association of Anesthesiologists, ANESTHESIOLOGY 2012. 2012 Abstract No. BOC09.
32. O'Gorman DA, O'Connell AW, Murphy KJ, Moriarty DC, Shiotani T, Regan CM. Nefiracetam prevents propofol-induced anterograde and retrograde amnesia in the rodent without compromising quality of anesthesia. Anesthesiology. 1998; 89:699-706. [PubMed: 9743408]
33. Pang R, Quartermain D, Rosman E, Turndorf H. Effect of propofol on memory in mice. Pharmacol Biochem Behav. 1993; 44:145-151. [PubMed: 8430117]
34. Ren Y, Zhang FJ, Xue QS, Zhao X, Yu BW. Bilateral inhibition of gamma-aminobutyric acid type A receptor function within the basolateral amygdala blocked propofol-induced amnesia and activity-regulated cytoskeletal protein expression inhibition in the hippocampus. Anesthesiology. 2008; 109:775-781. [PubMed: 18946287]
35. Veselis RA, Pryor KO, Reinsel RA, Li Y, Mehta M, Johnson R Jr. Propofol and midazolam inhibit conscious memory processes very soon after encoding: An event-related potential study of familiarity and recollection in volunteers. Anesthesiology. 2009; 110:295-312. [PubMed: 19194157]
36. Hauer D, Ratano P, Morena M, Scaccianoce S, Briegel I, Palmery M, Cuomo V, Roozendaal B, Schelling G, Campolongo P. Propofol enhances memory formation via an interaction with the endocannabinoid system. Anesthesiology. 2011; 114:1380-1388. [PubMed: 21532463]
37. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, Prada C, Greenberg SM, Bacskai BJ, Frosch MP. Characterization of amyloid deposition in the APPswe/ PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis. 2006; 24:516-524. [PubMed: 17029828]
38. Xiong H, Callaghan D, Wodzinska J, Xu J, Premyslova M, Liu QY, Connelly J, Zhang W. Biochemical and behavioral characterization of the double transgenic mouse model (APPswe/ PS1dE9) of Alzheimer's disease. Neurosci Bull. 2011; 27:221-232. [PubMed: 21788993]
39. Zhang Y, Dong Y, Wu X, Lu Y, Xu Z, Knapp A, Yue Y, Xu T, Xie Z. The mitochondrial pathway of anesthetic isoflurane-induced apoptosis. J Biol Chem. 2010; 285:4025-4037. [PubMed: 20007710]
40. Jazvinscak Jembrek M, Svob Strac D, Vlainic J, Pericic D. The role of transcriptional and translational mechanisms in flumazenil-induced up-regulation of recombinant GABA(A) receptors. Neurosci Res. 2008; 61:234-241. [PubMed: 18453026]
41. Zhang Y, Xu Z, Wang H, Dong Y, Shi HN, Culley DJ, Crosby G, Marcantonio ER, Tanzi RE, Xie Z. Anesthetics isoflurane and desflurane differently affect mitochondrial function, learning, and memory. Ann Neurol. 2012; 71:687-698. [PubMed: 22368036]
42. Bianchi SL, Tran T, Liu C, Lin S, Li Y, Keller JM, Eckenhoff RG, Eckenhoff MF. Brain and behavior changes in 12-month-old Tg2576 and nontransgenic mice exposed to anesthetics. Neurobiol Aging. 2008; 29:1002-1010. [PubMed: 17346857]
43. Zheng H, Dong Y, Xu Z, Crosby G, Culley DJ, Zhang Y, Xie Z. Sevoflurane anesthesia in pregnant mice induces neurotoxicity in fetal and offspring mice. Anesthesiology. 2013; 118:516-526. [PubMed: 23314109]
44. Shen X, Dong Y, Xu Z, Wang H, Miao C, Soriano SG, Sun D, Baxter MG, Zhang Y, Xie Z. Selective anesthesia-induced neuroinflammation in developing mouse brain and cognitive impairment. Anesthesiology. 2013; 118:502-515. [PubMed: 23314110]
45. Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: The calcium-apoptosis link. Nat Rev Mol Cell Biol. 2003; 4:552-565. [PubMed: 12838338]
46. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. Beta-secretase protein and activity are increased in the neo-cortex in Alzheimer disease. Arch Neurol. 2002; 59:1381-1389. [PubMed: 12223024]
47. Xie Z, Dong Y, Maeda U, Moir RD, Xia W, Culley DJ, Crosby G, Tanzi RE. The inhalation anesthetic isoflurane induces a vicious cycle of apoptosis and amyloid beta-protein accumulation. J Neurosci. 2007; 27:1247-1254. [PubMed: 17287498]
48. Ondo WG, Hunter C. Flumazenil, a GABA antagonist, may improve features of Parkinson's disease. Mov Disord. 2003; 18:683-685. [PubMed: 12784272]
49. Thornberry NA, Lazebnik Y. Caspases: Enemies within. Science. 1998; 281:1312-1316. [PubMed: 9721091]
50. Luchetti S, Huitinga I, Swaab DF. Neurosteroid and GABA-A receptor alterations in Alzheimer's disease, Parkinson's disease and multiple sclerosis. Neuroscience. 2011; 191:6-21. [PubMed: 21514366]
51. Rissman RA, Mobley WC. Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer's disease. J Neurochem. 2011; 117:613-622. [PubMed: 21388375]
52. Mizukami K, Grayson DR, Ikonomovic MD, Sheffield R, Armstrong DM. GABAA receptor beta 2 and beta 3 subunits mRNA in the hippocampal formation of aged human brain with Alzheimerrelated neuropathology. Brain Res Mol Brain Res. 1998; 56:268-272. [PubMed: 9602147]
53. Criollo A, Galluzzi L, Maiuri MC, Tasdemir E, Lavandero S, Kroemer G. Mitochondrial control of cell death induced by hyperosmotic stress. Apoptosis. 2007; 12:3-18. [PubMed: 17080328]
54. Pearn ML, Hu Y, Niesman IR, Patel HH, Drummond JC, Roth DM, Akassoglou K, Patel PM, Head BP. Propofol neurotoxicity is mediated by p75 neurotrophin receptor activation. Anesthesiology. 2012; 116:352-361. [PubMed: 22198221]
55. Whittington RA, Virag L, Marcouiller F, Papon MA, El Khoury NB, Julien C, Morin F, Emala CW, Planel E. Propofol directly increases tau phosphorylation. PLoS One. 2011; 6:e16648. [PubMed: 21304998]
56. Krzisch M, Sultan S, Sandell J, Demeter K, Vutskits L, Toni N. Propofol anesthesia impairs the maturation and survival of adult-born hippocampal neurons. Anesthesiology. 2013; 118:602-610. [PubMed: 23314165]
57. Bayona NA, Gelb AW, Jiang Z, Wilson JX, Urquhart BL, Cechetto DF. Propofol neuroprotection in cerebral ischemia and its effects on low-molecular-weight antioxidants and skilled motor tasks. Anesthesiology. 2004; 100:1151-1159. [PubMed: 15114212]
58. Zhang Y, Dong Y, Xu Z, Xie Z. Propofol and magnesium attenuate isoflurane induced caspase-3 activation via inhibiting mitochondrial permeability transition pore. Med Gas Res. 2012; 2:20. [PubMed: 22901676]
59. Rossaint J, Rossaint R, Weis J, Fries M, Rex S, Coburn M. Propofol: Neuroprotection in an in vitro model of traumatic brain injury. Crit Care. 2009; 13:R61. [PubMed: 19397790]
60. Minkeviciene R, Rheims S, Dobszay MB, Zilberter M, Hartikainen J, Fulop L, Penke B, Zilberter Y, Harkany T, Pitkanen A, Tanila H. Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci. 2009; 29:3453-3462. [PubMed: 19295151]
61. Schulze-Bonhage A, Elger CE. Induction of partial epileptic seizures by flumazenil. Epilepsia. 2000; 41:186-192. [PubMed: 10691115]